Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 1
2018 1
2019 2
2020 2
2022 6
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
Hanna C, Kurian KM, Williams K, Watts C, Jackson A, Carruthers R, Strathdee K, Cruickshank G, Dunn L, Erridge S, Godfrey L, Jefferies S, McBain C, Sleigh R, McCormick A, Pittman M, Halford S, Chalmers AJ. Hanna C, et al. Neuro Oncol. 2020 Dec 18;22(12):1840-1850. doi: 10.1093/neuonc/noaa104. Neuro Oncol. 2020. PMID: 32347934 Free PMC article. Clinical Trial.
Targeting DNA repair in gliomas.
Beckta JM, Bindra RS, Chalmers AJ. Beckta JM, et al. Curr Opin Neurol. 2019 Dec;32(6):878-885. doi: 10.1097/WCO.0000000000000760. Curr Opin Neurol. 2019. PMID: 31592790 Review.
Factors affecting the radiation response in glioblastoma.
Aiyappa-Maudsley R, Chalmers AJ, Parsons JL. Aiyappa-Maudsley R, et al. Neurooncol Adv. 2022 Sep 25;4(1):vdac156. doi: 10.1093/noajnl/vdac156. eCollection 2022 Jan-Dec. Neurooncol Adv. 2022. PMID: 36325371 Free PMC article. Review.
Correcting the drug development paradigm for glioblastoma requires serial tissue sampling.
Singh K, Hotchkiss KM, Parney IF, De Groot J, Sahebjam S, Sanai N, Platten M, Galanis E, Lim M, Wen PY, Minniti G, Colman H, Cloughesy TF, Mehta MP, Geurts M, Arrillaga-Romany I, Desjardins A, Tanner K, Short S, Arons D, Duke E, Wick W, Bagley SJ, Ashley DM, Kumthekar P, Verhaak R, Chalmers AJ, Patel AP, Watts C, Fecci PE, Batchelor TT, Weller M, Vogelbaum MA, Preusser M, Berger MS, Khasraw M. Singh K, et al. Nat Med. 2023 Oct;29(10):2402-2405. doi: 10.1038/s41591-023-02464-8. Nat Med. 2023. PMID: 37488293 No abstract available.
CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.
Walls GM, Oughton JB, Chalmers AJ, Brown S, Collinson F, Forster MD, Franks KN, Gilbert A, Hanna GG, Hannaway N, Harrow S, Haswell T, Hiley CT, Hinsley S, Krebs M, Murden G, Phillip R, Ryan AJ, Salem A, Sebag-Montefoire D, Shaw P, Twelves CJ, Walker K, Young RJ, Faivre-Finn C, Greystoke A. Walls GM, et al. Clin Transl Radiat Oncol. 2020 Sep 22;25:61-66. doi: 10.1016/j.ctro.2020.09.006. eCollection 2020 Nov. Clin Transl Radiat Oncol. 2020. PMID: 33072895 Free PMC article.
14 results